On March 18, 2013, Aastrom Biosciences (ASTM) reported financial results for the fourth quarter and full year ended December 31, 2012. Management also provided a business update for 2013. Below we outline the recent financial results and comment on the business plan for 2013, and beyond. We conclude that the stock is under-valued and an attractive long-term investment given the sales opportunity for ixmyelocel-T in both CLI and DCM, but that a lack of cash and catalysts will keep a lid on the shares over the near term.
The company reported negligible revenue of $0.019 million in the fourth quarter 2012. Revenue for the full year 2012 totaled a similar negligible amount of $0.021 million, all derived from the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|